You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePrednisolone
Accession NumberDB00860  (APRD00197)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]
Structure
Thumb
Synonyms
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
Hydroretrocortine
Metacortandralone
PRDL
Prednisolona
Prednisolonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ak Tate Oph Sus 1%Suspension1 %OphthalmicSandoz Canada Incorporated1985-12-312008-08-07Canada
Diopred Suspension 1%Suspension1 %OphthalmicSandoz Canada Incorporated1994-12-31Not applicableCanada
Flo-predSuspension15 mg/5mLOralTaro Pharmaceuticals U.S.A., Inc.2008-01-17Not applicableUs
Inflamase Forte Oph Soln 1%Liquid10 mgOphthalmicIolab Pharmaceuticals1988-12-311996-09-09Canada
Inflamase Forte Ophthalmic Solution 1%Solution1 %OphthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc1996-08-202004-07-13Canada
Inflamase MildLiquid.125 %OphthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc1995-12-312002-07-04Canada
Inflamase Oph Soln 0.125%Liquid1.25 mgOphthalmicIolab Pharmaceuticals1988-12-311996-09-09Canada
Minims Prednisolone Sodium Phosphate 0.5%Solution / drops0.5 %Ophthalmic; TopicalValeant Canada Lp/valeant Canada s.e.c.1995-12-31Not applicableCanada
Novo-prednisolone 5mgTablet5 mgOralNovopharm Limited1967-12-312005-08-10Canada
OmnipredSuspension10 mg/mLOphthalmicAlcon Laboratories, Inc.2007-11-06Not applicableUs
Orapred ODTTablet, orally disintegrating30 mg/1OralConcordia Pharmaceuticals Inc.2006-06-01Not applicableUs
Orapred ODTTablet, orally disintegrating10 mg/1OralShionogi Inc.2006-06-012016-10-13Us
Orapred ODTTablet, orally disintegrating10 mg/1OralConcordia Pharmaceuticals Inc.2006-06-01Not applicableUs
Orapred ODTTablet, orally disintegrating15 mg/1OralShionogi Inc.2006-06-012016-10-13Us
Orapred ODTTablet, orally disintegrating15 mg/1OralConcordia Pharmaceuticals Inc.2006-06-01Not applicableUs
Orapred ODTTablet, orally disintegrating30 mg/1OralShionogi Inc.2006-06-012016-10-13Us
PediapredLiquid5 mgOralSanofi Aventis Canada Inc1998-09-23Not applicableCanada
Pediapred - Liq 6.7mg/5mlLiquid5 mgOralFisons Corporation Ltd.1995-12-311998-08-12Canada
PMS-prednisoloneSolution5 mgOralPharmascience Inc2002-03-19Not applicableCanada
PMS-prednisolone Sod Phos Oph Sol Forte 1%Solution / drops1 %OphthalmicPharmascience Inc1992-12-31Not applicableCanada
Pred ForteSuspension / drops10 mg/mLOphthalmicAllergan, Inc.1973-06-01Not applicableUs
Pred ForteSuspension / drops10 mg/mLOphthalmicA S Medication Solutions Llc1973-06-01Not applicableUs
Pred ForteSuspension / drops10 mg/mLOphthalmicA S Medication Solutions Llc1973-06-01Not applicableUs
Pred Forte 1%Solution / drops1 %OphthalmicAllergan Inc1974-12-31Not applicableCanada
Pred MildSuspension / drops1.2 mg/mLOphthalmicAllergan, Inc.1972-12-01Not applicableUs
Pred MildSuspension / drops1.2 mg/mLOphthalmicPhysicians Total Care, Inc.2012-11-01Not applicableUs
Pred MildSuspension / drops1.2 mg/mLOphthalmicPreferred Pharmaceuticals, Inc2012-03-05Not applicableUs
Pred Mild 0.12%Solution / drops0.12 %OphthalmicAllergan Inc1974-12-31Not applicableCanada
Prednisolone AcetateSuspension10 mg/mLOphthalmicPhysicians Total Care, Inc.2002-11-04Not applicableUs
Prednisolone AcetateSuspension / drops10 mg/mLOphthalmicA S Medication Solutions1994-12-15Not applicableUs
Prednisolone AcetateSuspension / drops10 mg/mLOphthalmicPacific Pharma, Inc.1997-08-19Not applicableUs
Prednisolone AcetateSuspension / drops10 mg/mLOphthalmicPreferred Pharmaceuticals, Inc.2012-10-23Not applicableUs
Prednisolone AcetateSuspension / drops10 mg/mLOphthalmicH.J. Harkins Company, Inc.1997-08-19Not applicableUs
Prednisolone AcetateSuspension / drops10 mg/mLOphthalmicA S Medication Solutions1994-12-15Not applicableUs
Prednisolone AcetateSuspension / drops10 mg/mLOphthalmicA S Medication Solutions1997-08-19Not applicableUs
Prednisolone AcetateSuspension / drops10 mg/mLOphthalmicSandoz Inc.1994-12-15Not applicableUs
Prednisolone AcetateSuspension / drops10 mg/1OphthalmicREMEDYREPACK INC.2013-04-12Not applicableUs
Prednisolone AcetateSuspension10 mg/mLOphthalmicClinical Solutions Wholesale1994-12-15Not applicableUs
Prednisolone Acetate Ophthalmic Suspension USP 1%Suspension1 %OphthalmicBausch & Lomb Pharmaceuticals Inc.Not applicableNot applicableCanada
Prednisolone Sodium PhosphateSolution5 mg/5mLOralSeton Pharmaceuticals, Llc2013-10-18Not applicableUs
Prednisolone Sodium PhosphateTablet, orally disintegrating30 mg/1OralPrasco Laboratories2015-10-21Not applicableUs
Prednisolone Sodium Phosphate 1% ForteLiquid; Solution / drops1 %OphthalmicRivex Ophthalmics Inc.1997-05-072003-07-28Canada
Prednisolone Sodium Phosphate ODTTablet, orally disintegrating10 mg/1OralPrasco Laboratories2015-10-21Not applicableUs
Prednisolone Sodium Phosphate ODTTablet, orally disintegrating15 mg/1OralPrasco Laboratories2015-10-21Not applicableUs
R.O.-predphate Tm ForteLiquid; Solution / drops1 %OphthalmicRichmond Pharmaceuticals Inc.1992-12-311997-08-11Canada
Ratio-prednisoloneSuspension1 %OphthalmicTeva Canada Limited1986-12-31Not applicableCanada
Sab-prednaseSolution1 %OphthalmicSabex IncNot applicableNot applicableCanada
Sandoz PrednisoloneSuspension0.12 %OphthalmicSandoz Canada Incorporated1993-12-31Not applicableCanada
Sandoz PrednisoloneSuspension1 %OphthalmicSandoz Canada Incorporated1993-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MillipredTablet5 mg/1OralZylera Pharmaceuticals, LLC2014-03-01Not applicableUs
MillipredSolution10 mg/5mLOralZylera Pharmaceuticals, LLC2014-03-01Not applicableUs
MillipredTablet5 mg/5mgOralLaser Pharmaceuticals, LLC2008-10-01Not applicableUs
MillipredSolution10 mg/5mLOralLaser Pharmaceuticals, LLC2009-07-01Not applicableUs
OrapredSolution15 mg/5mLOralShionogi Inc.2000-12-142016-02-22Us
PediapredSolution5 mg/5mLOralRoyal Pharmaceuticals2003-03-26Not applicableUs
PrednisoloneSolution15 mg/5mLOralHi Tech Pharmacal Co., Inc.2003-02-27Not applicableUs
PrednisoloneSolution15 mg/5mLOralRebel Distributors Corp2003-02-27Not applicableUs
PrednisoloneSolution15 mg/5mLOralTeva Pharmaceuticals USA Inc1998-12-11Not applicableUs
PrednisoloneSolution15 mg/5mLOralPreferred Pharmaceuticals, Inc2003-02-27Not applicableUs
PrednisoloneSolution15 mg/5mLOralAidarex Pharmaceuticals LLC1998-12-11Not applicableUs
PrednisoloneSolution15 mg/5mLOralMed Vantx, Inc.1998-12-11Not applicableUs
PrednisoloneSyrup15 mg/5mLOralClinical Solutions Wholesale2007-09-21Not applicableUs
PrednisoloneSyrup15 mg/5mLOralPreferred Pharmaceuticals, Inc.2013-10-25Not applicableUs
PrednisoloneSolution15 mg/5mLOralDispensing Solutions, Inc.2003-02-27Not applicableUs
PrednisoloneSyrup5 mg/5mLOralPhysicians Total Care, Inc.2003-02-28Not applicableUs
PrednisoloneSolution15 mg/5mLOralA S Medication Solutions2003-02-27Not applicableUs
PrednisoloneSolution15 mg/5mLOralApotheca Inc.2003-02-27Not applicableUs
PrednisoloneSolution15 mg/5mLOralProficient Rx LP2003-02-27Not applicableUs
PrednisoloneSyrup15 mg/5mLOralEthex Corporation2004-05-10Not applicableUs
PrednisoloneSyrup15 mg/5mLOralQualitest Pharmaceuticals2007-09-21Not applicableUs
PrednisoloneSyrup15 mg/5mLOralPhysicians Total Care, Inc.2003-02-28Not applicableUs
PrednisoloneSolution15 mg/5mLOralDIRECT RX2014-01-01Not applicableUs
PrednisoloneSolution15 mg/5mLOralStat Rx USA2003-02-27Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralQualitest Pharmaceuticals2009-05-26Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralAtlantic Biologicals Corps2005-04-25Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralMorton Grove Pharmaceuticals, Inc.2004-10-04Not applicableUs
Prednisolone Sodium PhosphateSolution / drops10 mg/mLOphthalmicMwi/Vet One1994-07-29Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralPhysicians Total Care, Inc.2005-03-03Not applicableUs
Prednisolone Sodium PhosphateTablet, orally disintegrating15 mg/1OralMylan Pharmaceuticals Inc.2014-12-08Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralUnit Dose Services2005-04-25Not applicableUs
Prednisolone Sodium PhosphateSolution / drops10 mg/mLOphthalmicButler Animal Health Supply1994-07-29Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralProficient Rx LP2005-04-25Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralPharmaceutical Associates, Inc.2005-04-25Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralCardinal Health2004-10-04Not applicableUs
Prednisolone Sodium PhosphateTablet, orally disintegrating30 mg/1OralMylan Pharmaceuticals Inc.2014-12-08Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralRebel Distributors Corp2009-12-01Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralA S Medication Solutions2005-04-25Not applicableUs
Prednisolone Sodium PhosphateSolution5 mg/5mLOralHi Tech Pharmacal Co., Inc.2003-03-26Not applicableUs
Prednisolone Sodium PhosphateSolution5 mg/5mLOralSeton Pharmaceuticals2003-03-26Not applicableUs
Prednisolone Sodium PhosphateSolution5 mg/5mLOralA S Medication Solutions2003-03-26Not applicableUs
Prednisolone Sodium PhosphateTablet, orally disintegrating10 mg/1OralMylan Pharmaceuticals Inc.2014-12-08Not applicableUs
Prednisolone Sodium PhosphateSolution / drops10 mg/mLOphthalmicBausch & Lomb Incorporated1994-07-29Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralAmneal Pharmaceuticals of New York, LLC2009-12-01Not applicableUs
Prednisolone Sodium Phosphate Oral SolutionSolution25 mg/5mLOralMission Pharmacal Company2012-10-01Not applicableUs
Veripred 20Solution20 mg/5mLOralZylera Pharmaceuticals, LLC2014-08-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Ak-PredNot Available
Decortin HNot Available
Delta-CortefNot Available
DeltacortrilNot Available
HydeltraNot Available
Hydeltra-TBANot Available
HydeltrasolNot Available
InflamaseNot Available
Key-PredNot Available
KlismacortNot Available
MeticorteloneNot Available
PanafcorteloneNot Available
PrecortalonNot Available
PredonineNot Available
PreloneNot Available
SoloneNot Available
SteroloneNot Available
UltracortenolNot Available
Brand mixtures
NameLabellerIngredients
BlephamideAllergan, Inc.
Blephamide Oph OntAllergan Inc
Blephamide Opht SuspensionAllergan Inc
Dioptimyd OintmentDioptic Pharmaceuticals Inc
Dioptimyd SuspensionDioptic Pharmaceuticals Inc
Metimyd Oph SusSchering Plough Canada Inc
Odan-cideOdan Laboratories Ltd
Pred-GAllergan, Inc.
Sulfacetamide Sodium and Prednisolone Sodium PhosphateRebel Distributors Corp
Vasocidin Ophthalmic SolutionIolab Pharmaceuticals
Salts
Name/CASStructureProperties
Prednisolone acetate
Thumb
  • InChI Key: LRJOMUJRLNCICJ-JZYPGELDSA-N
  • Monoisotopic Mass: 402.204238692
  • Average Mass: 402.4807
DBSALT000254
Prednisolone sodium phosphate
125-02-0
Thumb
  • InChI Key: VJZLQIPZNBPASX-WFFZFITINA-L
  • Monoisotopic Mass: 484.123893702
  • Average Mass: 484.3876
DBSALT000785
prednisolone sodium succinate
ThumbNot applicableDBSALT001634
Prednisolone tebutate
7681-14-3
Thumb
  • InChI Key: HUMXXHTVHHLNRO-KAJVQRHHSA-N
  • Monoisotopic Mass: 458.266838948
  • Average Mass: 458.587
DBSALT000786
Prednisolone tertiary butylacetate
ThumbNot applicableDBSALT001635
Categories
UNII9PHQ9Y1OLM
CAS number50-24-8
WeightAverage: 360.444
Monoisotopic: 360.193674006
Chemical FormulaC21H28O5
InChI KeyOIGNJSKKLXVSLS-VWUMJDOOSA-N
InChI
InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
IUPAC Name
(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Pharmacology
IndicationFor the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders.
Structured Indications
PharmacodynamicsPrednisolone is a synthetic glucocorticoid used as antiinflammatory or immunosuppressive agent. Prednisolone is indicated in the treatment of various conditions, including congenital adrenal hyperplasia, psoriatic arthritis, systemic lupus erythematosus, bullous dermatitis herpetiformis, seasonal or perennial allergic rhinitis, allergic corneal marginal ulcers, symptomatic sarcoidosis, idiopathic thrombocytopenic purpura in adults, leukemias and lymphomas in adults, and ulcerative colitis. Glucocorticoids are adrenocortical steroids and cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.
Mechanism of actionGlucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
AbsorptionReadily absorbed by gastrointestinal tract, peak plasma concentration is reached 1-2 hours after administration.
Volume of distributionNot Available
Protein bindingVery high (>90%)
Metabolism

Excreted in the urine as either free or glucoconjugate.

Route of eliminationNot Available
Half life2-3 hours
ClearanceNot Available
ToxicityLD50=500 mg/kg (oral, rat), short-term side effects include high blood glucose levels and fluid retention. Long term side effects include Cushing's syndrome, weight gain, osteoporosis, glaucoma, type II diabetes and adrenal suppression.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Prednisone Action PathwayDrug actionSMP00440
Prednisolone Action PathwayDrug actionSMP00441
Prednisone Metabolism PathwayDrug metabolismSMP00631
Prednisolone Metabolism PathwayDrug metabolismSMP00632
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Prednisolone is combined with 1,10-Phenanthroline.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Prednisolone.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Prednisolone.Approved
AcetaminophenThe serum concentration of Prednisolone can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Prednisolone.Withdrawn
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Prednisolone.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Prednisolone.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Prednisolone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Prednisolone.Approved
AfatinibThe serum concentration of Prednisolone can be increased when it is combined with Afatinib.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Prednisolone.Experimental
AlbendazoleThe serum concentration of Prednisolone can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinPrednisolone may decrease the antineoplastic activities of Aldesleukin.Approved
AldosteroneThe serum concentration of Prednisolone can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Prednisolone can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Prednisolone can be increased when it is combined with Alfentanil.Approved, Illicit
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Prednisolone.Approved
ALT-110The risk or severity of adverse effects can be increased when Prednisolone is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Prednisolone can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Prednisolone can be decreased when combined with Aluminum phosphate.Approved
AmantadineThe serum concentration of Prednisolone can be increased when it is combined with Amantadine.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ambenonium.Approved
Aminohippuric acidThe serum concentration of Prednisolone can be increased when it is combined with Aminohippuric acid.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Prednisolone.Approved
AmiodaroneThe metabolism of Prednisolone can be decreased when combined with Amiodarone.Approved, Investigational
AmiodaroneThe serum concentration of Prednisolone can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Prednisolone can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Prednisolone can be increased when it is combined with Amlodipine.Approved
Amphotericin BPrednisolone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Prednisolone can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Prednisolone can be increased when it is combined with Amsacrine.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Prednisolone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Prednisolone.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Prednisolone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Prednisolone.Approved, Investigational
AprepitantThe serum concentration of Prednisolone can be increased when it is combined with Aprepitant.Approved, Investigational
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Prednisolone resulting in a loss in efficacy.Approved
AstemizoleThe serum concentration of Prednisolone can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Prednisolone can be decreased when combined with Atazanavir.Approved, Investigational
AtazanavirThe serum concentration of Prednisolone can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Prednisolone can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Prednisolone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Prednisolone can be increased when it is combined with Atorvastatin.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Prednisolone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Prednisolone.Withdrawn
AzelastineThe serum concentration of Prednisolone can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Prednisolone can be increased when it is combined with Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Prednisolone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prednisolone.Approved, Investigational
BazedoxifeneThe serum concentration of Prednisolone can be increased when it is combined with Bazedoxifene.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Prednisolone.Investigational
BendroflumethiazidePrednisolone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Prednisolone.Withdrawn
BenzocaineThe serum concentration of Prednisolone can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Prednisolone.Approved
BepridilThe serum concentration of Prednisolone can be increased when it is combined with Bepridil.Approved, Withdrawn
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Prednisolone.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Prednisolone.Approved, Investigational
BexaroteneThe serum concentration of Prednisolone can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Prednisolone can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateThe bioavailability of Prednisolone can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe metabolism of Prednisolone can be decreased when combined with Boceprevir.Approved
BoceprevirThe serum concentration of Prednisolone can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Prednisolone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Prednisolone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Prednisolone can be increased when it is combined with Bosutinib.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prednisolone.Approved
BromocriptineThe serum concentration of Prednisolone can be increased when it is combined with Bromocriptine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Prednisolone.Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Prednisolone.Withdrawn
BumetanidePrednisolone may increase the hypokalemic activities of Bumetanide.Approved
BuprenorphineThe serum concentration of Prednisolone can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Prednisolone can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Prednisolone.Approved
CaffeineThe serum concentration of Prednisolone can be increased when it is combined with Caffeine.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prednisolone.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Prednisolone can be decreased when combined with Calcium carbonate.Approved
CanagliflozinThe serum concentration of Prednisolone can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Prednisolone can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Prednisolone can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Prednisolone can be increased when combined with Carbamazepine.Approved, Investigational
CarbamazepineThe serum concentration of Prednisolone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbimazoleThe serum concentration of Prednisolone can be decreased when it is combined with Carbimazole.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Prednisolone.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Prednisolone can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Prednisolone can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Prednisolone.Experimental
CDX-110The risk or severity of adverse effects can be increased when Prednisolone is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prednisolone.Approved, Investigational
CeritinibThe serum concentration of Prednisolone can be increased when it is combined with Ceritinib.Approved
ChloroquineThe serum concentration of Prednisolone can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazidePrednisolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Prednisolone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorpromazineThe serum concentration of Prednisolone can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Prednisolone can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Prednisolone can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidonePrednisolone may increase the hypokalemic activities of Chlorthalidone.Approved
CholesterolThe serum concentration of Prednisolone can be increased when it is combined with Cholesterol.Experimental
CholestyramineCholestyramine can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cholic AcidThe serum concentration of Prednisolone can be decreased when it is combined with Cholic Acid.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Prednisolone.Experimental
CilazaprilThe serum concentration of Prednisolone can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Prednisolone can be decreased when it is combined with Cimetidine.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Prednisolone can be increased when it is combined with Citalopram.Approved
ClarithromycinThe metabolism of Prednisolone can be decreased when combined with Clarithromycin.Approved
ClarithromycinThe serum concentration of Prednisolone can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Prednisolone can be decreased when combined with Clemastine.Approved
ClofazimineThe serum concentration of Prednisolone can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Prednisolone can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Prednisolone.Approved
ClotrimazoleThe metabolism of Prednisolone can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Prednisolone can be decreased when combined with Cobicistat.Approved
CobicistatThe serum concentration of Prednisolone can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Prednisolone can be increased when it is combined with Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColforsinThe serum concentration of Prednisolone can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Prednisolone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Prednisolone can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Prednisolone.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Prednisolone is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Prednisolone can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Prednisolone.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Prednisolone.Approved, Investigational
CyclosporineThe metabolism of Prednisolone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Prednisolone.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Prednisolone.Investigational
DabrafenibThe serum concentration of Prednisolone can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Prednisolone can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Prednisolone can be increased when it is combined with Dactinomycin.Approved
DarunavirThe metabolism of Prednisolone can be decreased when combined with Darunavir.Approved
DarunavirThe serum concentration of Prednisolone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Prednisolone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Prednisolone can be decreased when it is combined with Daunorubicin.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Prednisolone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Prednisolone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Prednisolone can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Prednisolone is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Prednisolone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Prednisolone.Investigational
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Prednisolone.Investigational
DesipramineThe serum concentration of Prednisolone can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Prednisolone.Approved
DesloratadineThe serum concentration of Prednisolone can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Prednisolone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Prednisolone can be increased when it is combined with Dextromethorphan.Approved
DichlorvosThe risk or severity of adverse effects can be increased when Prednisolone is combined with Dichlorvos.Vet Approved
DiclofenacThe serum concentration of Prednisolone can be increased when it is combined with Diclofenac.Approved, Vet Approved
DienestrolThe serum concentration of Prednisolone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Prednisolone can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednisolone.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Prednisolone.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Prednisolone.Approved
DihydroergotamineThe metabolism of Prednisolone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteronePrednisolone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Prednisolone can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Prednisolone can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prednisolone.Approved, Investigational
DonepezilThe risk or severity of adverse effects can be increased when Prednisolone is combined with Donepezil.Approved
DoxazosinThe serum concentration of Prednisolone can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Prednisolone can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Prednisolone can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Prednisolone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Prednisolone can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Prednisolone can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Prednisolone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Prednisolone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Prednisolone.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Prednisolone.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Prednisolone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Prednisolone is combined with Edrophonium.Approved
EfavirenzThe serum concentration of Prednisolone can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Prednisolone can be increased when it is combined with Elbasvir.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Prednisolone.Approved
EnalaprilThe serum concentration of Prednisolone can be increased when it is combined with Enalapril.Approved, Vet Approved
EnoxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Prednisolone can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Prednisolone.Approved
ErgonovineThe serum concentration of Prednisolone can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Prednisolone can be increased when it is combined with Ergotamine.Approved
ErythromycinThe metabolism of Prednisolone can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Prednisolone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Prednisolone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Prednisolone can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Prednisolone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Prednisolone can be increased when it is combined with Estrone.Approved
Etacrynic acidPrednisolone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Prednisolone.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Prednisolone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Prednisolone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Prednisolone.Approved
EtoposideThe serum concentration of Prednisolone can be increased when it is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Prednisolone.Approved, Investigational
EtravirineThe serum concentration of Prednisolone can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Prednisolone.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Prednisolone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Prednisolone.Investigational
FelodipineThe serum concentration of Prednisolone can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Prednisolone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Prednisolone.Approved
FentanylThe serum concentration of Prednisolone can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fenthion.Vet Approved
FexofenadineThe serum concentration of Prednisolone can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Prednisolone can be increased when it is combined with Fidaxomicin.Approved
FingolimodPrednisolone may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Prednisolone.Approved, Withdrawn
FluconazoleThe metabolism of Prednisolone can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Prednisolone.Vet Approved
FluoxetineThe serum concentration of Prednisolone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteronePrednisolone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlupentixolThe serum concentration of Prednisolone can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Prednisolone can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Prednisolone can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Prednisolone.Approved, Investigational
FluvoxamineThe metabolism of Prednisolone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Prednisolone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Prednisolone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Prednisolone can be increased when combined with Fosphenytoin.Approved
FosphenytoinThe serum concentration of Prednisolone can be decreased when it is combined with Fosphenytoin.Approved
FurosemidePrednisolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Prednisolone can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Prednisolone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Prednisolone can be increased when it is combined with Gefitinib.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Prednisolone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Prednisolone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ginkgo biloba.Approved, Nutraceutical
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Prednisolone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Prednisolone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Prednisolone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Prednisolone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Prednisolone.Approved
GlyburideThe serum concentration of Prednisolone can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Prednisolone can be increased when it is combined with Glycerol.Experimental
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Prednisolone.Approved
Gramicidin DThe serum concentration of Prednisolone can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Grepafloxacin.Withdrawn
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Prednisolone.Investigational
HaloperidolThe serum concentration of Prednisolone can be increased when it is combined with Haloperidol.Approved
HexestrolThe serum concentration of Prednisolone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Prednisolone.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Prednisolone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Prednisolone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednisolone.Approved, Investigational
HydrochlorothiazidePrednisolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Prednisolone can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazidePrednisolone may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Prednisolone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Prednisolone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Prednisolone.Approved
IdelalisibThe serum concentration of Prednisolone can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Prednisolone can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Prednisolone can be increased when it is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Prednisolone.Approved
IndapamidePrednisolone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Prednisolone can be decreased when combined with Indinavir.Approved
IndinavirThe serum concentration of Prednisolone can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Prednisolone can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Prednisolone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Prednisolone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Prednisolone is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Prednisolone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Prednisolone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Prednisolone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Prednisolone.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Prednisolone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Prednisolone.Approved
IsavuconazoniumThe metabolism of Prednisolone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Prednisolone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Prednisolone.Withdrawn
IsradipineThe metabolism of Prednisolone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Prednisolone can be decreased when combined with Itraconazole.Approved, Investigational
ItraconazoleThe serum concentration of Prednisolone can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Prednisolone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Prednisolone can be increased when it is combined with Ivermectin.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Prednisolone.Experimental
KetamineThe serum concentration of Prednisolone can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe metabolism of Prednisolone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoconazoleThe serum concentration of Prednisolone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Prednisolone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Prednisolone.Approved
LansoprazoleThe serum concentration of Prednisolone can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Prednisolone can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Leflunomide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Prednisolone can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Prednisolone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Prednisolone.Approved
LiothyronineThe serum concentration of Prednisolone can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Prednisolone can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Prednisolone.Approved
LisinoprilThe serum concentration of Prednisolone can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Prednisolone.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Lomefloxacin.Approved
LomitapideThe serum concentration of Prednisolone can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Prednisolone can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Prednisolone can be decreased when combined with Lopinavir.Approved
LopinavirThe serum concentration of Prednisolone can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Prednisolone can be increased when it is combined with Loratadine.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Prednisolone.Approved
LosartanThe serum concentration of Prednisolone can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Prednisolone can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Prednisolone.Approved
LuliconazoleThe serum concentration of Prednisolone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Prednisolone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Prednisolone.Approved, Investigational
MagaldrateThe bioavailability of Prednisolone can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Prednisolone can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Prednisolone can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Prednisolone can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prednisolone.Approved
Magnesium TrisilicateThe bioavailability of Prednisolone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Prednisolone is combined with Malathion.Approved, Investigational
MaprotilineThe serum concentration of Prednisolone can be increased when it is combined with Maprotiline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Prednisolone.Approved
MebendazoleThe serum concentration of Prednisolone can be increased when it is combined with Mebendazole.Approved, Vet Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednisolone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Prednisolone.Approved
MefloquineThe serum concentration of Prednisolone can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Prednisolone can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Prednisolone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Memantine.Approved, Investigational
MeprobamateThe serum concentration of Prednisolone can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prednisolone.Approved
MestranolThe serum concentration of Prednisolone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Prednisolone.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone.Approved
MethadoneThe serum concentration of Prednisolone can be increased when it is combined with Methadone.Approved
MethallenestrilThe serum concentration of Prednisolone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Methanesulfonyl Fluoride.Investigational
MethimazoleThe serum concentration of Prednisolone can be decreased when it is combined with Methimazole.Approved
MethyclothiazidePrednisolone may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteronePrednisolone may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazonePrednisolone may increase the hypokalemic activities of Metolazone.Approved
MetoprololThe serum concentration of Prednisolone can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Prednisolone can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Prednisolone can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Prednisolone can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe therapeutic efficacy of Prednisolone can be decreased when used in combination with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Prednisolone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Prednisolone.Approved
MinaprineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Minaprine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Prednisolone.Approved, Investigational
MitomycinThe serum concentration of Prednisolone can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Prednisolone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Prednisolone can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MivacuriumMivacurium may increase the adverse neuromuscular activities of Prednisolone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prednisolone.Investigational
ModafinilThe serum concentration of Prednisolone can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Prednisolone can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Prednisolone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednisolone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Prednisolone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Prednisolone.Investigational
NafcillinThe serum concentration of Prednisolone can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Prednisolone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Prednisolone is combined with Nalidixic Acid.Approved
NaltrexoneThe serum concentration of Prednisolone can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Prednisolone.Approved, Vet Approved
NaringeninThe serum concentration of Prednisolone can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Prednisolone.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Prednisolone.Investigational
NefazodoneThe metabolism of Prednisolone can be decreased when combined with Nefazodone.Approved, Withdrawn
NefazodoneThe serum concentration of Prednisolone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Prednisolone can be decreased when combined with Nelfinavir.Approved
NelfinavirThe serum concentration of Prednisolone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Nemonoxacin.Investigational
NeostigmineThe serum concentration of Prednisolone can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Prednisolone.Approved
NetupitantThe serum concentration of Prednisolone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Prednisolone can be increased when combined with Nevirapine.Approved
NevirapineThe serum concentration of Prednisolone can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Prednisolone can be increased when it is combined with Nicardipine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Prednisolone is combined with Nicorandil.Approved
NifedipineThe serum concentration of Prednisolone can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Prednisolone.Approved
NilotinibThe metabolism of Prednisolone can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Prednisolone.Approved, Withdrawn
NisoldipineThe serum concentration of Prednisolone can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Prednisolone can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Prednisolone can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Prednisolone.Investigational
NorethisteroneThe serum concentration of Prednisolone can be decreased when it is combined with Norethisterone.Approved
NorfloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ofloxacin.Approved
OlaparibThe metabolism of Prednisolone can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prednisolone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prednisolone.Approved
OmeprazoleThe serum concentration of Prednisolone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Prednisolone.Vet Approved
OsimertinibThe serum concentration of Prednisolone can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Prednisolone.Approved
OxandrolonePrednisolone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Prednisolone.Approved
OxymetholonePrednisolone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prednisolone.Withdrawn
P-NitrophenolThe serum concentration of Prednisolone can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Prednisolone.Approved, Vet Approved
PalbociclibThe serum concentration of Prednisolone can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Prednisolone can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Prednisolone can be increased when it is combined with Pantoprazole.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Prednisolone.Approved
ParoxetineThe serum concentration of Prednisolone can be increased when it is combined with Paroxetine.Approved, Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Prednisolone can be increased when combined with Pentobarbital.Approved, Vet Approved
PentobarbitalThe serum concentration of Prednisolone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Prednisolone can be increased when it is combined with Perindopril.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Prednisolone.Approved, Withdrawn
PhenobarbitalThe metabolism of Prednisolone can be increased when combined with Phenobarbital.Approved
PhenobarbitalThe serum concentration of Prednisolone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Prednisolone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Prednisolone.Approved, Vet Approved
PhenytoinThe metabolism of Prednisolone can be increased when combined with Phenytoin.Approved, Vet Approved
PhenytoinThe serum concentration of Prednisolone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednisolone.Approved, Investigational
PimozideThe serum concentration of Prednisolone can be increased when it is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Prednisolone.Approved, Investigational
PiretanidePrednisolone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Prednisolone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prednisolone.Approved, Investigational
Platelet Activating FactorThe serum concentration of Prednisolone can be decreased when it is combined with Platelet Activating Factor.Experimental
Polyestradiol phosphateThe serum concentration of Prednisolone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazidePrednisolone may increase the hypokalemic activities of Polythiazide.Approved
PonatinibThe serum concentration of Prednisolone can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Prednisolone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PosaconazoleThe serum concentration of Prednisolone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Prednisolone.Approved, Investigational
PravastatinThe serum concentration of Prednisolone can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Prednisolone can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Prednisolone can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Prednisolone can be increased when combined with Primidone.Approved, Vet Approved
PrimidoneThe serum concentration of Prednisolone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Prednisolone can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Prednisolone can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromestrieneThe serum concentration of Prednisolone can be increased when it is combined with Promestriene.Investigational
PromethazineThe serum concentration of Prednisolone can be increased when it is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Prednisolone.Approved
PropafenoneThe serum concentration of Prednisolone can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Prednisolone can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Prednisolone can be increased when it is combined with Protriptyline.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Prednisolone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pyridostigmine.Approved
QuercetinThe serum concentration of Prednisolone can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Prednisolone can be increased when it is combined with Quinacrine.Approved
QuinestrolThe serum concentration of Prednisolone can be increased when it is combined with Quinestrol.Approved
QuinethazonePrednisolone may increase the hypokalemic activities of Quinethazone.Approved
QuinidineThe serum concentration of Prednisolone can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Prednisolone can be increased when it is combined with Quinine.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Prednisolone.Approved
RanitidineThe serum concentration of Prednisolone can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Prednisolone can be increased when it is combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Prednisolone.Withdrawn
ReboxetineThe serum concentration of Prednisolone can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Prednisolone can be increased when it is combined with Regorafenib.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Prednisolone.Approved, Investigational
ReserpineThe serum concentration of Prednisolone can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prednisolone.Experimental, Investigational
RifabutinThe metabolism of Prednisolone can be increased when combined with Rifabutin.Approved
RifabutinThe serum concentration of Prednisolone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe metabolism of Prednisolone can be increased when combined with Rifampicin.Approved
RifampicinThe serum concentration of Prednisolone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Prednisolone can be increased when combined with Rifapentine.Approved
RifapentineThe serum concentration of Prednisolone can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Prednisolone can be increased when it is combined with Rilpivirine.Approved
RitonavirThe serum concentration of Prednisolone can be increased when it is combined with Ritonavir.Approved, Investigational
RitonavirThe metabolism of Prednisolone can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Prednisolone.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Prednisolone.Approved
RolapitantThe serum concentration of Prednisolone can be increased when it is combined with Rolapitant.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Prednisolone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rosoxacin.Approved
S EquolThe serum concentration of Prednisolone can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Prednisolone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prednisolone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Prednisolone.Approved
SaquinavirThe metabolism of Prednisolone can be decreased when combined with Saquinavir.Approved, Investigational
SaquinavirThe serum concentration of Prednisolone can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Prednisolone.Approved
ScopolamineThe serum concentration of Prednisolone can be increased when it is combined with Scopolamine.Approved
SecoisolariciresinolThe serum concentration of Prednisolone can be increased when it is combined with Secoisolariciresinol.Investigational
SelegilineThe serum concentration of Prednisolone can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Prednisolone.Approved, Investigational
SertralineThe serum concentration of Prednisolone can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Prednisolone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Prednisolone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Prednisolone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Prednisolone can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Prednisolone.Approved
SirolimusThe serum concentration of Prednisolone can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Prednisolone.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Prednisolone.Approved
SorafenibThe serum concentration of Prednisolone can be increased when it is combined with Sorafenib.Approved, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Sparfloxacin.Approved
SpironolactoneThe serum concentration of Prednisolone can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Prednisolone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Prednisolone.Investigational
St. John's WortThe serum concentration of Prednisolone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololPrednisolone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StaurosporineThe serum concentration of Prednisolone can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Prednisolone can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Prednisolone can be decreased when it is combined with Streptozocin.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Prednisolone.Approved
SulfinpyrazoneThe serum concentration of Prednisolone can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Prednisolone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Prednisolone.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Prednisolone.Approved, Investigational
SumatriptanThe serum concentration of Prednisolone can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Prednisolone can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Prednisolone.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Prednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Prednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe serum concentration of Prednisolone can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Prednisolone.Approved, Investigational
TacrolimusThe serum concentration of Prednisolone can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Prednisolone can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Prednisolone can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Prednisolone.Approved
TelaprevirThe serum concentration of Prednisolone can be increased when it is combined with Telaprevir.Approved
TelithromycinThe metabolism of Prednisolone can be decreased when combined with Telithromycin.Approved
TelithromycinThe serum concentration of Prednisolone can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Prednisolone can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Temafloxacin.Withdrawn
TemsirolimusThe serum concentration of Prednisolone can be increased when it is combined with Temsirolimus.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Prednisolone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Prednisolone.Vet Approved
TerazosinThe serum concentration of Prednisolone can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Prednisolone can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Prednisolone.Approved
TesmilifeneThe serum concentration of Prednisolone can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Prednisolone can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Prednisolone is combined with TG4010.Investigational
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Prednisolone.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Prednisolone.Approved
TiboloneThe serum concentration of Prednisolone can be increased when it is combined with Tibolone.Approved
TicagrelorThe serum concentration of Prednisolone can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Prednisolone can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Prednisolone.Investigational
TocilizumabThe serum concentration of Prednisolone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibPrednisolone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Prednisolone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Prednisolone.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Prednisolone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Prednisolone.Approved
TolvaptanThe serum concentration of Prednisolone can be increased when it is combined with Tolvaptan.Approved
TorasemidePrednisolone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Prednisolone.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Prednisolone.Approved, Investigational
TrazodoneThe serum concentration of Prednisolone can be decreased when it is combined with Trazodone.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Prednisolone is combined with Trichlorfon.Vet Approved
TrichlormethiazidePrednisolone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Prednisolone can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Prednisolone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Prednisolone can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Prednisolone can be increased when it is combined with Trimipramine.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Prednisolone.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Prednisolone.Withdrawn
TroleandomycinThe serum concentration of Prednisolone can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Prednisolone.Investigational, Withdrawn
VenlafaxineThe metabolism of Prednisolone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Prednisolone can be decreased when combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Prednisolone.Approved, Investigational
VinblastineThe serum concentration of Prednisolone can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Prednisolone can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Prednisolone can be increased when it is combined with Vinorelbine.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Prednisolone.Approved, Investigational
VoriconazoleThe metabolism of Prednisolone can be decreased when combined with Voriconazole.Approved, Investigational
VoriconazoleThe serum concentration of Prednisolone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinPrednisolone may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prednisolone.Approved
ZeranolThe serum concentration of Prednisolone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Prednisolone.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Prednisolone can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Prednisolone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prednisolone.Withdrawn
Food Interactions
  • Avoid alcohol. Avoid caffeine.
  • Take with food to reduce gastric irritation.
References
Synthesis Reference

Gunther Bellmann, “Process for producing a sterile prednisolone gel.” U.S. Patent US5811417, issued September 22, 1998.

US5811417
General ReferencesNot Available
External Links
ATC CodesD07AA03R01AD52S02BA03A07EA01S01CA02V03AB05D07CA03D07XA02S01CB02C05AA04A01AC54S03BA02S02CA01R01AD02S03CA02H02AB06D07BA01S01BA04S01BB02
AHFS Codes
  • 52:08.08
  • 68:04.00
PDB EntriesNot Available
FDA labelDownload (101 KB)
MSDSDownload (72.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9918
Blood Brain Barrier+0.9383
Caco-2 permeable-0.5096
P-glycoprotein substrateSubstrate0.7861
P-glycoprotein inhibitor INon-inhibitor0.7847
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7463
CYP450 2C9 substrateNon-substrate0.8496
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9406
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9418
CYP450 2C19 inhibitorNon-inhibitor0.9253
CYP450 3A4 inhibitorNon-inhibitor0.8902
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9095
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9597
BiodegradationNot ready biodegradable0.925
Rat acute toxicity1.8914 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.95
hERG inhibition (predictor II)Non-inhibitor0.584
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Akorn inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Bel mar laboratories inc
  • Schering corp sub schering plough corp
  • Alpharma uspd inc
  • Apotex inc richmond hill
  • Hi tech pharmacal co inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Vintage pharmaceuticals llc
  • We pharmaceuticals inc
  • Wockhardt eu operations (swiss) ag
  • Muro pharmaceutical inc
  • Teva pharmaceuticals usa inc
  • Halsey drug co inc
  • Ferndale laboratories inc
  • Barr laboratories inc
  • Cm bundy co
  • Elkins sinn div ah robins co inc
  • Everylife
  • John j ferrante
  • Heather drug co inc
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Lannett co inc
  • Marshall pharmacal corp
  • Panray corp sub ormont drug and chemical co inc
  • L perrigo co
  • Phoenix laboratories inc
  • Purepac pharmaceutical co
  • Private formulations inc
  • Roxane laboratories inc
  • Sandoz inc
  • Sperti drug products inc
  • Superpharm corp
  • Tablicaps inc
  • Udl laboratories inc
  • Valeant pharmaceuticals international
  • Vitarine pharmaceuticals inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Pfizer laboratories div pfizer inc
  • Central pharmaceuticals inc
  • Alcon laboratories inc
  • Allergan pharmaceutical
  • Taro pharmaceuticals usa inc
  • Merck and co inc
  • Novartis pharmaceuticals corp
  • Pharmafair inc
  • Alcon universal ltd
  • Bausch and lomb pharmaceuticals inc
  • Sola barnes hind
  • Shionogi pharma inc
  • Ucb inc
  • Amneal pharmaceuticals
  • Paddock laboratories inc
  • Pharmaceutical assoc inc
Packagers
Dosage forms
FormRouteStrength
OintmentOphthalmic; Topical
SuspensionOphthalmic
SuspensionOral15 mg/5mL
LiquidOphthalmic10 mg
SolutionOphthalmic1 %
LiquidOphthalmic.125 %
LiquidOphthalmic1.25 mg
SolutionOral10 mg/5mL
TabletOral5 mg/5mg
TabletOral5 mg/1
Solution / dropsOphthalmic; Topical0.5 %
TabletOral5 mg
LiquidOral5 mg
SolutionOral5 mg
Solution / dropsOphthalmic1 %
Suspension / dropsOphthalmic10 mg/mL
Suspension / dropsOphthalmic1.2 mg/mL
Solution / dropsOphthalmic0.12 %
OintmentOphthalmic
Suspension / dropsOphthalmic
SolutionOral15 mg/5mL
SyrupOral15 mg/5mL
SyrupOral5 mg/5mL
SuspensionOphthalmic10 mg/mL
Suspension / dropsOphthalmic10 mg/1
SolutionOral5 mg/5mL
Solution / dropsOphthalmic10 mg/mL
Tablet, orally disintegratingOral10 mg/1
Tablet, orally disintegratingOral15 mg/1
Tablet, orally disintegratingOral30 mg/1
SolutionOral25 mg/5mL
Liquid; solution / dropsOphthalmic1 %
SuspensionOphthalmic0.12 %
SuspensionOphthalmic1 %
SolutionOphthalmic
Solution / dropsOphthalmic
LiquidOphthalmic
SolutionOral20 mg/5mL
Prices
Unit descriptionCostUnit
Orapred ODT 48 15 mg Dispersible Tablet Box289.42USD box
Pred Forte 1% Suspension 15ml Bottle97.79USD bottle
PrednisoLONE Sodium Phosphate 1% Solution 10ml Bottle72.82USD bottle
Pred Forte 1% Suspension 10ml Bottle68.06USD bottle
Econopred Plus 1% Suspension 10ml Bottle63.44USD bottle
Solu-Medrol Act-O-Vial 1 g/vial61.25USD vial
Solu-Medrol 1 g/vial60.04USD vial
Pediapred 6.7 mg/5ml Solution 120ml Bottle57.77USD bottle
Pred Mild 0.12% Suspension 10ml Bottle44.33USD bottle
Econopred Plus 1% Suspension 5ml Bottle40.99USD bottle
Solu-Medrol Act-O-Vial 500 mg/vial39.96USD vial
Medrol (Pak) 21 4 mg tablet Disp Pack39.3USD disp
Solu-Medrol 500 mg/vial39.17USD vial
Pred Forte 1% Suspension 5ml Bottle37.12USD bottle
Prednisolone sod ph powder36.11USD g
PrednisoLONE Acetate 1% Suspension 15ml Bottle35.46USD bottle
PrednisoLONE Sodium Phosphate 1% Solution 15ml Bottle34.41USD bottle
Pred Mild 0.12% Suspension 5ml Bottle33.98USD bottle
Methylprednisolone Sod Succin. 1 g/vial32.47USD vial
Solu-medrol 1 gm vial24.43USD vial
PrednisoLONE Acetate 1% Suspension 10ml Bottle24.02USD bottle
Solu-medrol (pf) 500 mg vial20.9USD vial
PrednisoLONE Sodium Phosphate 1% Solution 5ml Bottle19.99USD bottle
Methylprednisolone Sod Succin. 500 mg/vial19.48USD vial
PrednisoLONE Acetate 1% Suspension 5ml Bottle15.99USD bottle
Solu-Medrol Act-O-Vial 125 mg/vial15.94USD vial
Solu-medrol 500 mg vial12.9USD vial
Depo-medrol 80 mg/ml vial11.67USD ml
Depo-Medrol 80 mg/ml11.51USD ml
Pred forte 1% eye drops10.32USD ml
Methylprednisolone Acetate 80 mg/ml9.01USD ml
Methylprednisolone Sod Succin. 125 mg/vial8.9USD vial
Depo-Medrol (Preserved) 80 mg/ml8.89USD ml
Orapred odt 30 mg tablet8.34USD tablet
Orapred odt 15 mg tablet7.97USD tablet
Methylprednisolone Acetate (P) 80 mg/ml6.97USD ml
Omnipred 1% eye drops6.78USD ml
Solu-Medrol Act-O-Vial 40 mg/vial6.72USD vial
Depo-medrol 40 mg/ml vial6.41USD ml
Depo-Medrol 40 mg/ml6.01USD ml
Pred Forte 1 % Suspension5.95USD ml
Solu-medrol (pf) 125 mg vial5.83USD vial
Depo-Medrol (Preserved) 40 mg/ml5.75USD ml
Prednisolone ac 1% eye drop5.75USD ml
Prednisol 1% eye drops5.69USD ml
Pred mild 0.12% eye drops5.14USD ml
Medrol 32 mg tablet5.13USD tablet
Methylprednisolone Acetate 40 mg/ml4.71USD ml
Methylprednisolone Acetate (P) 40 mg/ml4.5USD ml
Econopred plus 1% eye drops3.93USD ml
Orapred odt 10 mg tablet3.89USD tablet
Depo-medrol 20 mg/ml vial3.78USD ml
Methylprednisolone Sod Succin. 40 mg/vial3.77USD vial
Prednisolone sod 1% eye drops3.7USD ml
Medrol 16 mg tablet3.5USD tablet
Prednisolone acetate powder3.36USD g
Prednisolone powder3.36USD g
Depo-Medrol 20 mg/ml2.63USD ml
Medrol 8 mg tablet2.3USD tablet
Ratio-Prednisolone 1 % Suspension2.03USD ml
Sandoz Prednisolone Acetate 1 % Suspension2.03USD ml
Pred Mild 0.12 % Suspension2.02USD ml
Medrol 4 mg tablet1.69USD tablet
Medrol 4 mg dosepak1.59USD each
Sandoz Prednisolone Acetate 0.12 % Suspension1.33USD ml
Millipred dp 5 mg dose pack tablet1.18USD tablet
Medrol 2 mg tablet0.84USD tablet
Orapred 15 mg/5 ml solution0.74USD ml
Millipred 5 mg tablet0.59USD tablet
Prelone 15 mg/5 ml syrup0.54USD ml
Prelone 15 mg/5ml Syrup0.47USD ml
PrednisoLONE Sodium Phosphate 15 mg/5ml Solution0.33USD ml
PrednisoLONE Sodium Phosphate 5 mg/5ml Solution0.23USD ml
Prednisolone 5 mg tablet0.14USD tablet
Pediapred 1 mg/ml Liquid0.14USD ml
Pms-Prednisolone 1 mg/ml Liquid0.07USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5178878 No1993-01-122010-01-12Us
US5881926 No1996-03-162016-03-16Us
US6024981 No1998-04-092018-04-09Us
US6071523 No1998-06-032018-06-03Us
US6221392 No1998-04-092018-04-09Us
US6399079 No1998-06-032018-06-03Us
US6656482 No1998-06-032018-06-03Us
US6740341 No1999-11-242019-11-24Us
US7799331 No2008-10-112028-10-11Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point235 °CPhysProp
water solubility223 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.62HANSCH,C ET AL. (1995)
logS-3.21ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.239 mg/mLALOGPS
logP1.66ALOGPS
logP1.27ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.58ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity98.49 m3·mol-1ChemAxon
Polarizability38.78 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaidis I, Andreadou I, Nikolaou M, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos P, Kremastinos DT: Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart. 2009 Sep;95(18):1502-7. doi: 10.1136/hrt.2009.168971. Epub 2009 May 28. [PubMed:19482847 ]
  2. Boudinot FD, D'Ambrosio R, Jusko WJ: Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm. 1986 Oct;14(5):469-93. [PubMed:2879901 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Frey BM, Frey FJ: Estimation of transcortin concentration by measurements of plasma protein-binding of prednisolone and by electroimmunodiffusion. Br J Clin Pharmacol. 1982 Feb;13(2):245-9. [PubMed:6800390 ]
  4. Ko HC, Almon RR, Jusko WJ: Effect of corticosteroid binding globulin on the pharmacokinetics of prednisolone in rats. Pharm Res. 1995 Jun;12(6):902-4. [PubMed:7667198 ]
  5. Angeli A, Frajria R, De Paoli R, Fonzo D, Ceresa F: Diurnal variation of prednisolone binding to serum corticosteroid-binding globulin in man. Clin Pharmacol Ther. 1978 Jan;23(1):47-53. [PubMed:563315 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  2. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 02:37